What is known and objective: It has been suggested that pyridoxine has an antilactogenic effect. Studies of the efficacy of pyridoxine in suppressing lactation have reported conflicting results. The aim of this review was to evaluate the effectiveness and safety of high-dose pyridoxine in post-partum lactation inhibition.
| WHAT IS KNOWN AND OBJECTIVE
Although the benefits of breastfeeding for mothers and infants are well documented, [1] [2] [3] under some conditions, lactation suppression might be indicated for the best interest of the lactating mother and/or the infant.
Some of the medical conditions that contraindicate breastfeeding include infants with the metabolic disorder classic galactosemia, mothers who are positive for human T-cell lymphotrophic virus type I or II, and untreated brucellosis, among others. 1, 2, 4 Furthermore, the lactating mother's use of some types of medications might necessitate avoiding breastfeeding, such as mothers undergoing chemotherapy. 1, 2 Lactation inhibition might also be needed following an infant death or miscarriage. 5, 6 When the decision to suppress lactation or not breastfeed an infant is made, the prevention of breast engorgement is essential to avoid associated complications, such as breast pain and mastitis. [5] [6] [7] Up to one-third of women who do not breastfeed and use nonpharmacological approaches, such as brassieres, binders, or ice packs, or analgesics to treat symptoms associated with lactation suppression may experience severe breast pain. 8 Several pharmacological agents for lactation inhibition have been studied. Oestrogen preparations given either alone or in combination with androgens have been shown to be effective in 40%-100% of women; however, due to their high rates of rebound lactation and the associated increased risk of thrombosis and pulmonary embolism, the use of these preparations is discouraged. 9 The dopamine agonists (bromocriptine and cabergoline) have also been reported to be effective in inhibiting puerperal lactation. 9, 10 However, the use of dopamine agonists is not recommended in the presence of hypertensive disorders of pregnancy, including pre-eclampsia, eclampsia, pregnancy-induced hypertension and post-partum hypertension, or in women with a history of puerperal psychosis. 11, 12 Similarly, variable results were reported with other agents, such as clomiphene, prostaglandin E, serotonin antagonists and pyridoxine. 9 Pyridoxine (ie vitamin B6) has been shown to have an antilactogenic effect. 13 The exact mechanism by which pyridoxine inhibits lactation is not well understood. However, pyridoxine is known to act as a co-enzyme that promotes the conversion of dopa to dopamine. The increase in dopamine formation in hypothalamic neurons and their major dendrites is thought to result in prolactin inhibition and consequent lactation inhibition. 14 Studies of the efficacy of pyridoxine in lactation suppression have reported conflicting results. 14, 15 No systematic review explicitly investigated the efficacy and safety of pyridoxine for post-partum lactation suppression. The objective of this systematic review was to evaluate the effectiveness and safety of pyridoxine in the inhibition of post-partum lactation.
| METHODS

| Selection criteria
All types of published trials that compared the efficacy and/or safety of pyridoxine to placebo or to other pharmacological agents for the inhibition of post-partum lactation were included in this review.
However, reviews, letters, conference papers and abstracts were excluded. Studies that evaluated pyridoxine efficacy in women who had already established lactation and trials published in languages other than English were also excluded from the review.
| Outcome measures
Studies that described any of the following efficacy and/or safety outcomes were evaluated: suppression of lactation, as indicated by clinical assessment, breast pain, engorgement and/or milk secretion (or as described by the trial), prolactin level and adverse events related to pyridoxine. The words "inhibition" and "suppression" of lactation were used interchangeably in this review to refer to the inhibition or suppression of lactation during the early period before lactation is established.
| Search strategy
We searched PubMed, Embase, ScienceDirect, CINAHL, AMED, the Cochrane library and the clinical trials registry to identify relevant literature. The key search terms that were used to identify relevant studies were "pyridoxine," "vitamin B6," "lactation," "breastfeeding," "breast milk," "inhibition," "suppression," "prevention" and "stop." The search terms were used in various combinations along with truncations (*) and relevant Boolean operators, depending on the database. Furthermore, manual searches of the references of the identified articles were performed to identify additional articles that
were not retrieved through the electronic searches. The search was limited to studies that included human subjects and were published in English. No limit was imposed on the year of publication of the studies, and the review included studies published as recently as 15 January 2016.
| Data extraction and management
RefWorks, which is a web-based reference management software program, was used to manage the retrieved references. 16 The primary reviewer (DS) conducted the initial search of the databases. This was followed by screening of the titles and abstracts of the retrieved articles by another reviewer (SS). The screening was validated by a second reviewer (AA) to ensure the comprehensiveness and relevance of the search. Full-text articles of studies that were judged to be potentially eligible during the title/abstract screening were retrieved. Finally, two authors (DS, SS) independently reviewed the full-text articles to ensure their suitability for inclusion. Any disagreements in the process were resolved through consensus. For the included studies, data were extracted independently by two of the authors (DS, SS). Any disagreements were resolved through discussion and adjudication by a third reviewer (AA) whenever necessary. A standardized data extraction tool was developed utilizing PRISMA items. 17 The extracted data were presented under the following headings: reference (author, year), objective, study design, population, intervention, comparator, outcome measures and key results. All extracted data were validated for accuracy through double entry by two authors.
| Quality assessment
All included studies were assessed independently by two authors to determine the risk of bias. Discrepancies were resolved through consensus. Randomized trials were assessed using the criteria outlined in the 
| RESULTS
| Characteristics of the included studies
Of the 2552 search results that were retrieved, seven studies [13] [14] [15] [20] [21] [22] [23] were considered to be eligible for inclusion in the review (Figure 1 ).
These studies included a total of 1155 participants, of which 471 women received pyridoxine. Three studies were randomized controlled trials (Table 1) , 14, 15, 20 whereas the remaining four studies were non-randomized controlled trials (Table 2) 13, [21] [22] [23] . The specific study designs of the non-randomized studies were not clearly defined in the articles. None of the included studies presented evidence of power analysis (ie sample size calculations); the largest study included a total of 482 participants, and four of the studies included less than 100
participants. Six studies were published in the 1970s, [13] [14] [15] [21] [22] [23] and only one study was published in the 1980s 20 (Table 1 and Table 2 ).
| Participants
Generally, the studies recruited post-partum women who did not breastfeed or had contraindications for breastfeeding. The participants' obstetric characteristics (eg parity and gestational week at delivery) were not described in any of the studies, and exclusion criteria
were not specified in many of the studies.
| Interventions
The studies compared pyridoxine with placebo, bromocriptine and/or stilboestrol. Pyridoxine was compared with placebo in four studies and with other pharmacological agents (bromocriptine or stilboestrol) in four studies. One trial compared women who received pyridoxine to suppress lactation to normally lactating women. Pyridoxine was administered orally in all of the studies, and the total daily dose ranged between 450 and 600 mg for 5-7 days.
The treatment was commenced shortly after delivery in all of the enrolled women.
| Outcome measures
The method of outcome assessment varied among the studies. Two studies assessed the effect of high-dose pyridoxine use on prolactin levels, 21, 23 whereas pyridoxine efficacy was evaluated clinically in six of the studies. [13] [14] [15] [20] [21] [22] However, different parameters were used to describe clinical efficacy, including breast discomfort, breast 
Departures from intended interventions
Low-to-moderate risk Participants adhered to the assigned interventions. After analysing the results of the assigned interventions, a second course of pyridoxine was provided to five patients who failed to suppress lactation
Missing data Low-to-moderate risk Of 375 questionnaires issued, seventy questionnaires were not completed, and 51 questionnaires were inadequately filled in. The 254 patients for whom full information was available were divided into four groups, and all of these patients were included in the analysis Measurement of outcomes Serious-to-critical risk Twenty-five patients were un-blinded to pyridoxine. These patients all (100%) ceased lactation within 1 wk, compared to 93% in the blinded group. A possibility of influencing outcome measures due to lack of blinding was present Selection of the reported result Low-to-moderate risk The outcome measurements and analyses are consistent with an a priori plan
Canales ES et al., 1976
Objective To investigate the influence of pyridoxine administration on prolactin release and milk production Design/Methodology Not well stated; described as a control trial Population Puerperal women on the first day after delivery with contraindications for breastfeeding due to medical reasons N=34 Outcome measures Breast tenderness, breast engorgement, lactation Rebound engorgement, lactation or increased lochia 6 wk post-partum
Results
• Stilboestrol was significantly more effective in inhibiting the onset of lactation than pyridoxine or the placebo (P<0.01) • Pyridoxine was only marginally more effective than placebo • Regarding the incidence of rebound phenomena, results were not statistically significant (P>0.3)
• No patients reported increased lochia
Others
Women were issued written advice concerning fluid restriction and the wearing of a firm brassiere. One patient reported calf tenderness on day 3 post-partum. The code was broken. The subject was found to be receiving pyridoxine, and a deep vein thrombosis was excluded
Risk of bias Criterion
Authors' judgement Support for judgement
Confounding Serious-to-critical risk Women were issued written advice that fluid restriction and the wearing of a firm brassiere would assist in preventing the onset of lactation. The differences in applying these instructions between the different groups were not measured, which can confound the results Selection of participants into the study
Unclear risk
No information was reported about the selection of participants into the study Classification of interventions Low-to-moderate risk Intervention status was well defined
Departures from intended interventions
Low-to-moderate risk No bias due to deviation from the intended intervention is expected. Women who received additional medications known to influence lactation (N= 14) or decided to breastfeed were excluded to avoid deviation from the intended intervention
consistency, breast engorgement and cessation of lactation. Safety was evaluated in only two of the studies.
Two of the included studies reported that the use of high-dose pyridoxine (ie 200 mg three times per day for 6 days) resulted in the suppression of lactation in approximately 95% of the enrolled subjects. 13, 14 In these two studies, 193 patients received pyridoxine, which accounted for 41% of the total number of patients who received pyridoxine in all of the included studies. Efficacy was assessed clinically in both of these studies. However, all other studies failed to demonstrate pyridoxine efficacy through either clinical assessment or prolactin level measurements. 15, [20] [21] [22] [23] No untoward side effects were reported in either of the two studies that assessed the safety of the use of high-dose pyridoxine.
14,20
| Quality assessment and risk of bias
The details for the risk of bias assessment for each study are presented in Table 1 and Table 2 . Overall, the risk of bias for most studies was low or low-to-moderate ( Figure 2 and Figure 3 ). 
Risk of bias
| DISCUSSION
Despite the availability of dopamine agonists (eg cabergoline and bromocriptine) for use in post-partum lactation inhibition, many maternal medical conditions necessitate avoiding the use of these agents due to safety concerns. These concerns highlight the need for alternative effective and safe agents. A small number of studies suggested that pyridoxine has an antilactogenic effect; however, data related to the clinical effectiveness and safety of pyridoxine are limited. This review evaluated the effectiveness and safety of pyridoxine in post-partum lactation inhibition.
Foukas was the first to report the effectiveness of high-dose pyridoxine in post-partum lactation suppression. 13 Thereafter, Marcus reaffirmed that finding. 14 In both studies, effectiveness was assessed clinically. However, all other studies failed to produce similar results through clinical assessment 15, [20] [21] [22] or prolactin level measurements. 21, 23 Similar conflicting results were reported with pyridoxine use for treating galactorrhoea-amenorrhoea syndromes. Initially, near the time at which
Foukas and Marcus published their findings, McIntosh suggested a role for pyridoxine in the management of women with hyperprolactinemia and galactorrhoea-amenorrhoea. 24 Later, pyridoxine was demonstrated to lack effectiveness for reducing prolactin levels in these patients. [25] [26] [27] These conflicting results make it difficult to confirm the effectiveness of pyridoxine for clinical use in post-partum lactation inhibition.
In our review, pyridoxine safety was not a concern, as no untoward side effects were reported. However, the assessment of pyridoxine safety was limited to only two of the included studies. 14, 20 The studies included in the current review used varying methods to assess lactation inhibition, including clinical evaluations and/ or laboratory investigations. Furthermore, the criteria used for clinical evaluations of pyridoxine efficacy were also defined in different ways in different studies. These criteria included leakage of milk, breast engorgement and the time of lactation cessation. Overall, the total number of patients who received pyridoxine was not very large (n=471 patients), and sample size calculations were not presented in any of the included studies. Furthermore, the specific study designs were not clearly defined in the non-randomized studies, 13, [21] [22] [23] and all of the studies included in the current review had been published for more than 35 years ago. [13] [14] [15] [20] [21] [22] [23] Based on these observations, the strength of the current evidence is not sufficient to recommend the routine use of pyridoxine for post-partum lactation inhibition in clinical practice.
This review was limited to literature published in the English language, and studies published in other languages were excluded, although such studies may contain valuable information for this review. The quality of the included studies is another limitation of this review. The study design was not well stated in many of the studies. We used Cochrane risk of bias assessment tools to evaluate how this weakness impacted the study quality, but the risk of bias appeared to be low to moderate.
| WHAT IS NEW AND CONCLUSION
The available evidence is conflicting and insufficient to confirm the effectiveness of high-dose pyridoxine in post-partum lactation inhibition. Limited data suggest that high-dose pyridoxine is safe in women who aim to inhibit lactation. However, larger and well-designed rand- 
